Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Low/Intermediate Risk MDS
NCT00074074Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2003
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of infliximab in myelodysplastic syndrome (MDS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Best response as measured by Cheson response criteria. Started Oct 2003; status: completed.
02
Drugs
infliximab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00074074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074074.